LFG
APGE

Larson Financial Group’s Apogee Therapeutics APGE Stock Holding History

Larson Financial Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.7K Buy
231
+13
+6% +$1.17K ﹤0.01% 1762
2026
Q1 		$18.3K Buy
218
+61
+39% +$4.43K ﹤0.01% 1894
2025
Q4 		$11.8K Buy
157
+84
+115% +$5.29K ﹤0.01% 2019
2025
Q3 		$2.9K Sell
73
-121
-62% -$4.62K ﹤0.01% 2557
2025
Q2 		$8.43K Buy
194
+164
+547% +$6.24K ﹤0.01% 1890
2025
Q1 		$1.12K Buy
+30
New +$1.16K ﹤0.01% 2356

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Larson Financial Group's APGE Position: Q2 2026 in Review

Larson Financial Group increased its Apogee Therapeutics (APGE) stake by 6% in Q2 2026, buying an estimated $1.17K and bringing the position to 231 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Larson Financial Group first reported a position in APGE in Q1 2025 and has held it in 6 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Larson Financial Group held 231 shares of Apogee Therapeutics worth $30.7K as of Q2 2026.
  • Larson Financial Group bought 13 Apogee Therapeutics shares in Q2 2026, an estimated $1.17K.
  • Apogee Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1762 holding.
  • Larson Financial Group first reported a position in Apogee Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.